Medical device developer OncoSil Medical has received ethics approval from Melbourne's largest public health service for its clinical study program for pancreatic cancer.
The company says approval by Monash Health, a oncology centre providing services to more than 1.5 million people, means it will be the lead Australian centre for OncoSil's clinical study into its pancreatic cancer treatment OncoPaC.
OncoSil, whose treatment involves the implantation of its product into a patient's pancreatic tumours via an endoscopic ultrasound, also said 12 centres had now agreed to participate in the study and it is in discussions with a further seven centres in Australia, Europe and the UK.
Share
